Significant Research

 
News Articles for Significant Research top ^
3D Mammography Significantly Increases the Detection of Breast Cancer Concludes a Study that Reviewed Close to Half a Million Exams Published in the Journal of the American Medical Association (JAMA) Canada NewsWire Study using Hologic 3D Mammography systems is the largest to date involving 139 doctors from 13 U.S. academic and community-based sites BEDFORD, Mass.
Sign-up for 3D Mammography Significantly Increases the Detection of Breast Cancer Concludes a Study that Reviewed Close to Half a Million Exams Published in the Journal of the American Medical Association (JAMA) investment picks
CIT Group Inc. (NYSE:CIT) cit.com , a leading provider of commercial lending and leasing services, today announced that it provided a senior secured credit facility to support Rosser Capital Partners’ significant investment in PetPeople, a specialty retail pet supply store that focuses on high quality, natural pet food.
Sign-up for CIT Provides Financing for Rosser Capital Partners’ Significant Investment in PetPeople investment picks
2014/7/26
Shareholder rights law firm Johnson & Weaver, LLP reminds investors of the September 16, 2014 lead plaintiff deadline in a securities class action lawsuit filed by the firm against Prosensa Holding N.V. (NASDAQ:RNA). The class action lawsuit was filed in the United States District Court for the Southern District of New York on behalf of the class (the “Class”). Those purchasers of the ordinary common shares of Prosensa pursuant and/or traceable to the Company's initial public offering (“IPO”) on or about June 28, 2013 and suffered significant losses are encouraged to contact Johnson & Weaver regarding your legal rights.
Sign-up for PROSENSA HOLDING N.V. SHAREHOLDER ALERT: Johnson & Weaver, LLP Reminds Investors of Upcoming September 16, 2014 Deadline; Encourages Investors with Significant Losses to Contact the Firm investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment.
Sign-up for Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects investment picks
Cognitive Deficit and Depression Symptoms Improve Significantly, Trial Data Shows GERMANTOWN, Md.
Sign-up for Neuralstem's NSI-189 Novel Neurogenic Compound Shows Significant Effect In Major Depressive Disorder investment picks
2014/7/7
Higher Economic Optimism Spurs Significant Increase in Investments by Canadians Canada NewsWire TD survey finds rising confidence has boosted annual total to 14 per cent of income TORONTO , July 7, 2014 /CNW/ - Rising stock markets are boosting investor confidence and leading Canadians to increase the share of income they invest, according to the latest TD Investor Insights Index.
Sign-up for Higher Economic Optimism Spurs Significant Increase in Investments by Canadians investment picks
IMAX Adds 19 Theatres With Shanghai Film Corp.
Sign-up for IMAX Adds 19 Theatres With Shanghai Film Corp. And Subsidiaries In Significant China Deal investment picks
CANTON, Ga., Sept.
Sign-up for Blue Water Finalizes Second Significant Equity Investment investment picks
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NYSE:PFE) today announced results of a pre-specified secondary analysis of the Eliquis Phase 3 AMPLIFY-EXT trial (A pixaban after the initial M anagement of P u L monary embol I sm and deep vein thrombosis with F irst-line therap Y - EXT ended Treatment). The analysis evaluated clinical and demographic predictors of all-cause hospitalization in patients with VTE, which includes deep vein thrombosis (DVT) and pulmonary embolism (PE). Results from this analysis demonstrated that during the 12-month extended treatment of VTE, Eliquis significantly reduced the risk of hospitalization versus placebo.
Sign-up for Secondary Analysis of AMPLIFY-EXT Examining Predictors of Hospitalization Presented at ESC Congress: Eliquis (apixaban) Significantly Reduced the Risk of All-Cause Hospitalization Versus Placebo in Patients with Venous Thromboembolism (VTE) investment picks
CALGARY , June 25, 2014 /PRNewswire/ - (TSX:PMT) - Perpetual Energy Inc. ("Perpetual", or the "Company") is pleased to announce that it has entered into definitive agreements with a joint venture partner (the "JV Partner") for a portion of its lands in the Edson area of West Central Alberta (the "East Edson Property"). The joint venture ("East Edson JV") will significantly accelerate Perpetual's net production and funds flow growth from the East Edson Property.
Sign-up for Perpetual Energy Inc. Announces $120 Million Joint Venture in the East Edson Area and Gas Over Bitumen Royalty Credit Monetization, Reports Related Significant Positive Reserves Update and Provides Updated Guidance for 2014 and 2015 investment picks
Study using Hologic 3D Mammography systems is the largest to date involving 139 doctors from 13 U.S. academic and community-based sites BEDFORD, Mass.
Sign-up for 3D Mammography Significantly Increases the Detection of Breast Cancer Concludes a Study that Reviewed Close to Half a Million Exams Published in the Journal of the American Medical Association (JAMA) investment picks
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from two Phase 3 studies of lumacaftor in combination with ivacaftor that showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV 1 ) in people ages 12 and older with cystic fibrosis (CF) who have two copies (homozygous) of the F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene.
Sign-up for Two 24-Week Phase 3 Studies of Lumacaftor in Combination with Ivacaftor Met Primary Endpoint with Statistically Significant Improvements in Lung Function (FEV1) in People with Cystic Fibrosis who have Two Copies of the F508del Mutation investment picks
Ascent Solar Technologies, Inc. ("Ascent") (NASDAQ: ASTI), a manufacturer of state-of-the-art, flexible thin-film photovoltaic modules integrated into off-grid applications and the company’s EnerPlex™ series of consumer products, announced today the achievement of a significant milestone related to the Definitive Agreement signed in December of 2013 with the Government of the Municipal City of Suqian in Jiangsu Province, China ("Suqian"). As previously announced under the Definitive Agreement, Suqian will build a facility to manufacture Ascent's proprietary Copper-Indium-Gallium-Selenium (CIGS) photovoltaic modules on flexible thin films.
Sign-up for Ascent Solar Reaches Significant Milestone for Its Proposed Joint Venture with the City of Suqian of Jiangsu Province, China investment picks
2014/7/2
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1128277&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Oriens Provides Significant Updates: Share Reduction Program to Be Initiated Today; Auditor Named & More investment picks
Diversity in the U.S. power supply—the most cost-effective means of managing the inherent risks in fuel costs and technology performance in generating power—could be dramatically reduced in coming decades, says a new study by IHS (NYSE: IHS), the leading global source of critical information and insight.
Sign-up for IHS Study: Diversity of United States Power Supply Could be Significantly Reduced in Coming Decades investment picks
RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus Canada NewsWire In addition, preliminary results from an Australian sponsored trial have yet to verify whether the mechanism of RVX-208 action may affect glucose metabolism.
Sign-up for RVX-208 Reduces Major Adverse Cardiovascular Events (MACE) Significantly in Patients with Diabetes Mellitus investment picks
2014/8/6
A study by EMA Research found that organizations using security analytics and threat analytics are nearly two times as confident of detecting security issues and 90 percent report reduced false alerts compared to those not using these tools.
Sign-up for Study Finds Security Analytics Significantly Decrease False Alerts investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Significant Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Significant Losses  |  Next: Silver Award